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Summary
Perioperative bleeding is a major concern in patients with factor VII (FVII) deficiency. Evaluating data of 95 FVII-deficient patients undergoing 110 surgical procedures (61 major, 49 minor), we assessed the impact of type of surgery, bleeding phenotype and FVII coagulant activity (FVII:C) levels on perioperative replacement therapy (RT). Compared to those with higher FVII:C levels, patients with <3% FVII:C received a higher number of RT doses (8 vs. 2, P = 0Á003) for a longer RT duration (3 days vs. 1 day, P = 0Á001), with no difference in RT dose. Similarly, patients with a history of major bleeds received a higher number of RT doses (8Á5 vs. 2-3, P = 0Á013) for a longer RT duration (2 days vs. 1 day, P = 0Á005) as compared to those with a history of minor bleeds or to asymptomatic patients. No difference in RT was found among major and minor surgical procedures. Overall, multivariate analysis showed that history of major bleeding was the only independent predictor of number of RT doses (b = 0Á352, P = 0Á001) and RT duration (b = 0Á405, P = 0Á018). Overall, a %20 lg/kg perioperative RT was efficacious in 95Á5% of cases. The infusion should be repeated %8 times in high-risk subsets (i.e. patients with a history of major bleeding).
Keywords: factor VII deficiency, bleeding disorders, surgery.
Inherited factor VII (FVII) deficiency is the most common of the rare autosomal recessive bleeding disorders, with an estimated prevalence of 1:300 000 in European countries (Mannucci et al, 2004; Mariani & Bernardi, 2009; Perry, 2002) . Affected individuals display a wide range of clinical phenotypes. About 50% of patients experience a mild clinical picture (i.e. mucocutaneous bleeds) that mimics that of a platelet disorder, but in 15-20% of cases life-or limb-threatening haemorrhages [i.e. central nervous system (CNS) bleeds, gastrointestinal (GI) bleeds or haemarthrosis] are consistently seen (Perry, 2002; Mariani & Bernardi, 2009 ). On the other hand, up to one-third of individuals with FVII deficiency is asymptomatic (Mariani et al, 2005) . These individuals are mainly diagnosed during family studies or after a haemostatic screen prior to surgery.
The relationship between the severity of clinical phenotype and FVII coagulant activity (FVII:C) has been recently demonstrated for non-surgical bleeds (Di Minno et al, 2013) . For surgical patients, a number of other variables (e.g. type of surgery, tissue/organ involved, type of anaesthesia) should be taken into account to define bleeding risk (Mariani et al, 2011) .
In our experience, perioperative bleeding is a major concern in patients with FVII deficiency (Kitchens & Lawson, 2013) , and validated recommendations about the perioperative management of replacement therapy (RT) with FVII are currently lacking.
In this study, by analysing the large database of the Seven Treatment Evaluation Registry (STER), we have evaluated whether specific clinical and laboratory characteristics could influence the clinical choice of the perioperative RT schedule in subjects with inherited FVII deficiency undergoing major and/or minor surgery.
clinical baseline information and describe data on treatment modalities and outcomes in patients with congenital FVII deficiency. The registry was proposed by the International F7 Study Group (www.targetseven.org) and approved by the Ethics Committees of all of the institutions involved. The STER protocol is available at http://www.ta rgetseven.org and published on http://clinicaltrials.gov (# NCT01269138). The STER Registry completed enrolment in February 2012 and included information related to 225 patients. Clinical and demographic data were collected for each patient. In each case, the type of bleeding was defined by the treating physicians, and patients were carefully characterized with respect to their bleeding phenotype by recording the number and type of bleeding events. FVII:C levels for the STER were assessed in a centralized European Quality Assurance (ISO 9001) certified laboratory.
In the present report, data about patients with FVII deficiency undergoing major and/or minor surgical procedures were analysed. The concomitant presence of reduced clotting factors other than FVII, von Willebrand factor deficiencies/abnormalities, abnormal platelet counts or platelet dysfunction were considered as exclusion criteria from the present study. Patients with missing data about perioperative RT, FVII:C, clinical phenotype and surgery outcome were also excluded. To avoid a relevant source of heterogeneity, only patients receiving recombinant activated FVII (rFVIIa, NovoSeven â ; Novo Nordisk, Bagsvaerd, Denmark)
were included in the current analysis. Surgical procedures were classified as major or minor according to standard criteria (Kitchens & Lawson, 2013) . In agreement with previously published criteria (Di Minno et al, 2013) , patients were stratified in tertiles according to FVII:C level (<3% cFVII, 3-20%, >20%) and, according to the clinical phenotype, as major bleeders (patients with a history of bleeding in a critical area or organ, i.e. CNS, GI and intra-articular), minor bleeders [patients with an history of mucocutaneous bleeds (excluding GI): epistaxis, gum bleeding, easy bruising, ecchymosis, umbilical cord stump bleeding, haemorrhoidal bleeding, subcutaneous or muscle haematoma, menorrhagia and haematuria] and asymptomatic subjects (non-bleeders: individual with a confirmed diagnosis of FVII deficiency who never experienced any spontaneous minor or major bleeding episode). Only bleeding episodes occurring before the index surgical procedure were taken into account to define the severity of the clinical phenotype.
For each surgical procedure, data about type of surgery, RT dose, number of RT doses and RT duration were evaluated. The occurrence of a perioperative bleed (until hospital discharge) and concomitant medical interventions have been recorded. STER study was approved by the ethics committee of the University of L'Aquila and registered in ClinicalTrials.gov: NCT01269138.
Statistical analysis
Continuous data were expressed as means AE SD, and categorical variables were expressed as percent. To compare continuous variables, an independent sample t test was performed. Because of skewed distribution of values, data on RT have been presented as median with inter-quartile range (IQR) and the Mann-Whitney U test (for comparing 2 groups) and the Kruskal-Wallis test (for comparing more than 2 groups) were used to compare non-parametric continuous variables. The chi-square test was employed to analyse categorical data. However, when the minimum expected value for categorical data was <5, the Fisher exact test was used. The whole population was stratified into quantitatively comparable tertiles according to FVII:C levels (1st: <3%; 2nd: 3-20%; 3rd: > 20%). A linear regression analysis was used to identify predictors of RT dose, number of RT doses and RT duration. In addition, separate logistic regression analyses were used to identify predictors of the use of a single-dose RT administration and concomitant use of anti-fibrinolytic drugs. In these multivariate analyses, gender, age, age at first bleeding episode, age at diagnosis, FVII:C levels, type of surgery and bleeding phenotype were the independent variables. This also allowed us to test the potential collinearity between bleeding phenotype and FVII: C levels. All results are expressed as 2-tailed values with statistical significance if P values <0Á05. Statistical analysis was performed with the SPSS 17 software (SPSS Inc., Chicago, IL, USA).
Results

Study population
Data on 113 patients with FVII deficiency undergoing surgery have been recorded in the STER registry. After excluding those treated with plasma-derived FVII (pd-FVII, n = 16) or fresh frozen plasma (FFP, n = 2), a total of 95 patients (52 females and 43 males with a similar mean age, Table I ) undergoing surgical procedures and receiving perioperative RT with rFVIIa were included in the present study. In this population, FVII:C levels ranged from <1% to 48Á7% (mean: 14Á14 AE 13Á35). Stratifying for residual FVII:C levels, tertiles yielded the following result: 30 subjects (31Á6%) exhibited <3% FVII:C, 31 (32Á6%) between 3% and 20% and the remaining 34 (35Á8%) had >20% FVII:C.
Stratification according to life-long bleeding tendency showed that 15 subjects (15Á8%) had a history of major bleeds, 32 (33Á7%) of minor bleeds and 48 (50Á5%) had always been asymptomatic. Among the 15 subjects with a history of major bleeds, 2 had experienced umbilical cord bleeding, 5 CNS, 7 haemarthrosis and 5 GI bleeds.
Among the 32 subjects with a history of minor bleedings, 5 had haemorrhoidal blood loss, 16 easy bruising, 25 epistaxis, 18 gum bleeds, 6 haematuria, 5 haemoperitoneum, 18 menorrhagia, 6 muscle haematomas and 13 subcutaneous haematomas.
Among the 95 patients enrolled, a history of previous post-operative bleeding was reported in 13 (13Á7%) subjects (2 with a history of major bleeding, 7 with a previous minor bleeding and 4 in asymptomatic subjects).
Surgical procedures (major surgery and minor surgery)
In these 95 subjects, 110 surgical procedures were carried out: 61 (55Á5%) major and 49 (44Á5%) minor. Surgical procedures were elective in all the cases but nine in whom an emergency surgery was performed. Surgical interventions performed are listed in Table II. Replacement therapy dose was 18Á0 lg/kg (IQR: 12Á6-30Á0), the number of RT doses was 2Á0 (IQR: 1-8) and RT duration was 1 day (IQR: 1-3). A single-dose RT with rFVIIa was used in 42 (38Á2%) procedures and a concomitant treatment with anti-fibrinolytic agents was reported in 29 procedures (26Á4%). Perioperative antithrombotic prophylaxis with heparin (in all cases low-molecular weight heparin) was used in six major and three minor surgical procedures (in 4 subjects with 3-20% FVII:C and in 5 subjects with >20% FVII:C).
Type of surgery (minor versus major)
No difference was found in RT dose, number of RT doses and RT duration among major and minor surgical procedures (Table III) FVII:C levels (<3%, 3-20%, >20%)
By stratifying results according to FVII:C levels, the number of RT doses and RT duration were higher in subjects with <3% FVII:C as compared to those with 3-20% or with >20% FVII:C, but no difference was found in RT dose (Table III) .
Of interest, these results were confirmed in those undergoing major surgical procedures, but not in those undergoing minor surgery (Fig 1) .
A single-dose of FVII was used in 10 procedures [27Á0% (95% CI: 15Á2-43Á3%)] in patients with <3% FVII:C, in 16 [43Á2% (95% CI: 28Á4-59Á4%)] with 3-20% FVII:C and in 16 [44Á4% (95% CI: 29Á3-60Á7%)] with >20% FVII:C (P for within group difference = 0Á229). A similar prevalence of concomitant treatment with anti-fibrinolytic agents was also reported in those with FVII:C < 3%, 3-20% and >20% [35Á1% (95% CI: 21Á6-51Á5%), 21Á6% (95% CI: 11Á2-37Á6%) and 22Á2% (95% CI: 11Á5-38Á5%), respectively; P for within group difference = 0Á331].
Bleeding history (major bleeds, minor bleeds and asymptomatic patients)
Those with a history of major bleeds received a higher number of RT doses and had a longer RT duration compared to those with a history of minor bleeds as well as to asymptomatic patients, without a difference in RT dose (Table III) . Of interest, these differences were confirmed in those undergoing major surgical procedures, but not in those undergoing minor surgery (Fig 2) .
Evaluating the bleeding history, a single-dose of FVII replacement was used in 2 [12Á5% (95% CI: 3Á10-38Á6%)] of those reporting a history of major bleeding, in 13 [33Á3% (95% CI: 20Á4-49Á3%)] of those with previous minor Minor bleeding, major bleeding and non-bleeding: definitions in Methods section. Age: similar among male and female subjects, P = 0Á731. Body weight: significantly higher in men than in women, P = 0Á010. Factor VII coagulant activity (FVII:C) significantly higher in males than in females, P = 0Á018.
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bleedings and in 27 [49Á1% (95% CI: 36Á2-62Á1%)] of asymptomatic subjects (P for within group difference = 0Á022). In detail, asymptomatic patients were treated with a single-dose of FVII more frequently than those with a history of major bleeding (OR: 6Á75, 95% CI: 1Á40-32Á54, P = 0Á010), with no significant difference as compared to patients with a history of minor bleeding (OR: 1Á93, 95% CI: 0Á824-4Á513, P = 0Á144). The prevalence of a concomitant treatment with anti-fibrinolytic agents was significantly higher in those with a history of major or minor bleeds as compared to asymptomatic subjects [56Á3% (95% CI: 32Á4-77Á5%) vs. 12Á7% (95% CI: 6Á20-24Á4%), OR: 8Á85 (95% CI: 2Á48-31Á25), P = 0Á001 and 33Á3% (95% CI: 20Á4-49Á3%) vs. 12Á7% (95% CI: 6Á20-24Á4%), OR: 3Á42 (95% CI: 1Á22-9Á61), P = 0Á022, respectively].
Multivariate analyses. In a multivariate analysis (linear regression model), after adjusting for all co-variates (see Methods section) and for the potential collinearity between bleeding phenotype and FVII:C levels, a history of major bleeding was the only independent predictor of number of RT doses (b = 0Á352, P = 0Á001) and RT duration (b = 0Á405, P always = 0Á018).
A logistic regression analysis confirmed that asymptomatic subjects were more likely to receive a single-dose RT as compared to those with a history of major bleedings [OR: 6Á76 (95% CI: 1Á40-32Á3), P = 0Á017]. The difference was not confirmed comparing those with a history of minor bleedings with asymptomatic subjects [OR: 1Á93 (95% CI: 0Á82-4Á50),
In a separate regression model, those with a history of major or minor bleeds received more often a concomitant treatment with anti-fibrinolytic agents as compared to 
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*Two with peri-operative bleeding. †One with peri-operative bleeding. Table III . Perioperative replacement therapy with rFVIIa (lg/kg) -stratification according to type of surgery, FVII levels, and bleeding history.
Type of surgery P Major surgery (n = 61)
Minor surgery (n = 49)
FVII:C levels
Bleeding history P Major bleeding (n = 16) Minor bleeding (n = 39) Asymptomatic (n = 55)
All values are presented as median (IQR); P values for non-parametric comparisons by using Mann-Whitney U test (for comparing 2 groups) and Kruskal-Wallis test (for comparing more than 2 groups). FVII:C, factor VII coagulant activity; IQR, interquartile range; rFVIIa, recombinant activated factor VII; RT, replacement therapy.
asymptomatic subjects [OR: 8Á816 (95% CI: 2Á484-31Á289), P = 0Á001 and OR: 3Á429 (95% CI: 1Á217-9Á656), P = 0Á020].
Surgical procedure outcome
RT with FVII was efficacious in 95Á5% of surgical procedures. Perioperative bleeding was reported by five subjects (4 females and 1 male), but only one of these required transfusion (2 units). Thus, three out of these five perioperative bleedings occurred in patients undergoing minor elective surgery (2 gynaecological and 1 oral surgery), one during a minor gynaecological emergency intervention and one during major elective orthopaedic surgery. The patient undergoing major elective surgery also received nadroparine (0Á3 ml once daily) for perioperative antithrombotic prophylaxis.
As detailed in Fig 3, when patients with perioperative bleeding were stratified according to life-long bleeding phenotype, two were asymptomatic, two were minor bleeders and one was a major bleeder. As to FVII:C categories, three (A) (B) Fig 1. RT dose, number of RT doses and RT duration (days) in patients with <3%, 3-20% and >20% FVII:C undergoing (A) major surgical procedures and (B) minor surgical procedures. FVII:C, factor VII coagulant activity; RT, replacement therapy. Differences among the 3 FVII:C tertiles: RT dose: P = 0Á185 in major surgical procedures and P = 0Á597 in minor surgical procedures. Number of RT doses: P < 0Á001 in major surgical procedures and P = 0Á180 in minor surgical procedures. Number of RT days: P < 0Á001 in major surgical procedures and P = 0Á103 in minor surgical procedures.
(A) (B)
Fig 2. Replacement therapy (RT) dose, number of RT doses and RT duration (days) in major bleeders, minor bleeders and non-bleeders undergoing (A) major surgical procedures and (B) minor surgical procedures. Differences among the three life-long bleeding severity groups: RT dose: P = 0Á127 in major surgical procedures and P = 0Á960 in minor surgical procedures. Number of RT doses: P = 0Á005 in major surgical procedures and P = 0Á110 in minor surgical procedures. Number of RT days: P = 0Á002 in major surgical procedures and P = 0Á336 in minor surgical procedures.
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ª 2017 John Wiley & Sons Ltd out of five patients experiencing postoperative bleeding had <3% FVII:C, the other two patients having 3-20% and >20% FVII:C, respectively. The five patients reporting perioperative bleeding received a 27Á9 lg/kg RT dose (IQR: 20Á2-113Á9) with eight RT doses (IQR: 1Á5-9Á5) and a RT duration of 1 day (IQR: 1-2).
Perioperative thrombosis occurred in two subjects undergoing major surgery (1 urological and 1 orthopaedic) and not receiving perioperative antithrombotic prophylaxis with heparin.
The cumulative in-hospital stay was 5Á0 days (IQR: 2-9), which was higher in those who underwent major rather than minor surgery [6Á0 days (IQR: 3-10) vs. 2Á0 days (IQR: 1-6),
No difference was found in the cumulative in-hospital stay according to FVII:C levels [<3% FVII:C: 7Á5 days (IQR: 2-12); 3-20% FVII:C: 3Á5 days (IQR: 1Á25-6Á0); >20% FVII:C: 4Á5 days (IQR: 2Á0-7Á0), P for within group difference = 0Á224] or to a history of bleeding [major bleeders: 4Á0 days (IQR: 1Á5-11Á5); minor bleeders: 5Á0 days (IQR: 2Á0-9Á0); asymptomatic: 4Á5 days (IQR: 1Á75-8Á25), P for within group difference = 0Á874].
Discussion
This is the first study reporting on the relationship between clinical and laboratory factors and the perioperative RT management of patients with FVII deficiency.
Overall, RT with rFVIIa was efficacious in 95Á5% of cases, as only five perioperative bleeds were reported, three of which occurred in subjects with <3% FVII:C and only one requiring blood cell transfusion.
Interestingly, we found that neither severity of FVII deficiency nor type of surgery (major versus minor) are determinants of the perioperative RT. In contrast, we showed that the severity of bleeding phenotype significantly impacted on RT, patients with an history of major bleeding receiving higher number of RT doses with a longer RT duration as compared to those with minor bleeding or to asymptomatic subjects. Of interest, these results were mainly confirmed in major but not in minor surgical procedures.
Further confirming this finding, besides results on the number of RT doses, we found that the concomitant use of anti-fibrinolytic agents progressively increased with increasing severity of bleeding phenotype (12Á7%, 33Á3% and 56Á3%, in asymptomatic subjects, minor bleeders and major bleeders, respectively). Although these results support the pro-haemostatic efficacy of anti-fibrinolytic agents and their good safety profile when concomitantly used with rFVIIa (Levi et al, 2002) , we do not have any data about the use of anti-fibrinolytic without concomitant treatment with rFVIIa.
Overall, these results argue for a history of major bleeding as a relevant risk factor for a more severe bleeding tendency in the perioperative period. These findings confirm and extend some of our recent data (Di Minno et al, 2013) showing that a history of major bleedings is a strong predictor of clinical severity of FVII deficiency.
It is important to highlight that these results were mainly confirmed in major but not in minor surgical procedures. This additional finding is useful to address the issue of perioperative RT in minor surgical procedures.
In most of cases, regardless of FVII:C levels, severity of bleeding phenotype and type of surgery, the perioperative RT was performed with a %20 lg/kg median dose.
Overall, this approach was efficacious in more than 95% of cases, with only five perioperative bleedings reported, three of which occurred in subjects with <3% FVII:C and only one required blood cell transfusion. However, the lack of a group not receiving RT hampers the possibility to assess efficacy and safety of perioperative RT.
Given the lack of recognized standard recommendations, the perioperative management of patients with FVII deficiency is particularly complex and RT is widely variable in terms of doses and length.
Although further studies are needed to address this issue, we can state that, based on data of the STER registry, the current choice is to treat patients with FVII deficiency 
